| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
The VHL (von Hippel-Lindau) E3 ubiquitin ligase complex. The compound binds to the VHL protein, recruiting the E3 ligase to ubiquitinate target proteins that are brought into proximity via a conjugated target-binding ligand.
|
|---|---|
| ln Vitro |
This linker-ligand conjugate has no intrinsic pharmacological activity; it is a synthetic building block. However, the VHL-binding moiety alone (without a target ligand) shows no degradation activity. It is used exclusively as a chemical tool.
|
| ln Vivo |
No in vivo activity is reported for the linker alone. In vivo activity would only be observed after conjugation to a target-protein ligand to form a complete PROTAC molecule, which can induce target degradation in animal models.
|
| Enzyme Assay |
A non-cell assay is performed to confirm VHL binding. The compound is incubated with purified VHL-Elongin B-Elongin C complex and a fluorescently labeled HIF-1alpha peptide. Binding affinity is measured by fluorescence polarization or TR-FRET, with IC50 typically in the low nanomolar range.
|
| Cell Assay |
The linker alone is not tested in cell assays; only the complete PROTAC is used. For validation, cells are treated with a PROTAC built from this linker (e.g., 0.1-10 uM, 4-24 h). Target protein degradation is assessed by Western blot. The linker itself should cause no degradation.
|
| Animal Protocol |
No animal studies are performed with the linker alone. Complete PROTAC molecules containing this linker are administered to mice (e.g., IV or IP, 1-50 mg/kg) to evaluate target degradation in vivo, pharmacokinetics, and efficacy in xenograft models.
|
| ADME/Pharmacokinetics |
The linker itself does not have a PK profile; the PK of a PROTAC incorporating it depends on the target-binding ligand and overall molecular weight. The C6 alkyl linker is designed to be metabolically stable and to provide appropriate spacing between the VHL ligand and the target binder.
|
| Toxicity/Toxicokinetics |
The linker alone is not intended for therapeutic use and shows no cytotoxicity at concentrations used for PROTAC synthesis (e.g., up to 10 uM in cell culture). The toxicity of any PROTAC containing this linker must be evaluated individually. Standard laboratory safety precautions apply.
|
| References | |
| Additional Infomation |
(S,R,S)-AHPC-Me-C6-NH2 is a research building block for the preparation of PROTAC degraders. The free NH2 group allows conjugation to target-binding ligands via amide bond formation. It is for research use only, not for diagnostic or therapeutic applications. Store at -20degC, away from moisture and light.
|
| Molecular Formula |
C30H45N5O4S
|
|---|---|
| Molecular Weight |
571.774406194687
|
| Exact Mass |
571.319
|
| CAS # |
2411422-49-4
|
| PubChem CID |
154584012
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
40
|
| Complexity |
844
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
S1C=NC(C)=C1C1C=CC(=CC=1)[C@H](C)NC([C@@H]1C[C@H](CN1C([C@H](C(C)(C)C)NC(CCCCCCN)=O)=O)O)=O
|
| InChi Key |
UGZLQBJANUBKTH-BOALBMDWSA-N
|
| InChi Code |
InChI=1S/C30H45N5O4S/c1-19(21-11-13-22(14-12-21)26-20(2)32-18-40-26)33-28(38)24-16-23(36)17-35(24)29(39)27(30(3,4)5)34-25(37)10-8-6-7-9-15-31/h11-14,18-19,23-24,27,36H,6-10,15-17,31H2,1-5H3,(H,33,38)(H,34,37)/t19-,23+,24-,27+/m0/s1
|
| Chemical Name |
(2S,4R)-1-[(2S)-2-(7-aminoheptanoylamino)-3,3-dimethylbutanoyl]-4-hydroxy-N-[(1S)-1-[4-(4-methyl-1,3-thiazol-5-yl)phenyl]ethyl]pyrrolidine-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7490 mL | 8.7448 mL | 17.4895 mL | |
| 5 mM | 0.3498 mL | 1.7490 mL | 3.4979 mL | |
| 10 mM | 0.1749 mL | 0.8745 mL | 1.7490 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
